Vinorelbine
- Generic Name
- Vinorelbine
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C45H54N4O8
- CAS Number
- 71486-22-1
- Unique Ingredient Identifier
- Q6C979R91Y
- Background
Vinorelbine is an anti-mitotic chemotherapy drug that is used in the treatment of several types of malignancies, including breast cancer and non-small cell lung cancer (NSCLC) . It was initially approved in the USA in 1990's for the treatment of NSCLC .
...
- Indication
Vinorelbine tartrate is indicated for adults in the treatment of advanced non-small cell lung cancer (NSCLC), as a single therapy or in combination with other chemotherapeutic drugs .
Used in relapsed or refractory Hodgkin lymphoma, in combination with other chemotherapy agents .
...
- Associated Conditions
- Locally Advanced Non-Small Cell Lung Cancer, Metastatic Breast Cancer, Metastatic Cervical Cancer, Metastatic Non-Small Cell Lung Cancer, Recurrent Cervical Cancer, Soft Tissue Sarcoma
- Associated Therapies
- -
Trastuzumab & Pertuzumab Followed by T-DM1 in MBC
- Conditions
- Interventions
- First Posted Date
- 2013-04-18
- Last Posted Date
- 2021-03-30
- Lead Sponsor
- Swiss Group for Clinical Cancer Research
- Target Recruit Count
- 208
- Registration Number
- NCT01835236
- Locations
- 🇨🇭
Hirslanden Klinik Aarau, Aarau, Switzerland
🇨🇭Kantonspital Aarau, Aarau, Switzerland
🇨🇭Kantonsspital Baden, Baden, Switzerland
Lapatinib+Vinorelbine vs Vinorelbine HER2 Positive Metastatic Breast Cancer Progressed After Lapatinib/Trastuzumab
- First Posted Date
- 2012-11-21
- Last Posted Date
- 2014-03-12
- Lead Sponsor
- National Cancer Center, Korea
- Target Recruit Count
- 150
- Registration Number
- NCT01730677
- Locations
- 🇰🇷
National Cancer Center, Goyang-si, Gyeonggi-do, Korea, Republic of
Effect of Endostar Combined With Chemotherapy and Radiotherapy on Blood Vessels and Microenvironment of Tumor for Non-small Cell Lung Cancer (NSCLC)
- Conditions
- Interventions
- First Posted Date
- 2012-09-19
- Last Posted Date
- 2012-09-19
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 15
- Registration Number
- NCT01687439
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, China
An Dose Escalation Trial of Oral BIBF 1120 in Combination With Intravenous Carboplatin and Vinorelbine in Elderly Patients With Advanced Non-Small Cell Lung Cancer - Stage IV (VENUS-2)
- Conditions
- Interventions
- First Posted Date
- 2012-09-12
- Last Posted Date
- 2015-01-26
- Lead Sponsor
- Aktion Bronchialkarzinom e.V.
- Target Recruit Count
- 8
- Registration Number
- NCT01683682
- Locations
- 🇩🇪
Klinikum Kassel GmbH, Kassel, Germany
🇩🇪Krankenhaus Großhansdorf, Großhansdorf, Germany
An Dose Escalation Trial of Oral BIBF 1120 in Combination With Intravenous Vinorelbine in Elderly Patients With Advanced Non Small Lung Cell Cancer - Stage IV (VENUS-1)
- Conditions
- Interventions
- First Posted Date
- 2012-09-12
- Last Posted Date
- 2016-01-18
- Lead Sponsor
- Aktion Bronchialkarzinom e.V.
- Target Recruit Count
- 7
- Registration Number
- NCT01684111
- Locations
- 🇩🇪
Klinikum der Universität München, München, Germany
🇩🇪Klinikum Kassel GmbH, Kassel, Hessen, Germany
🇩🇪Thoraxklinik Universitätsklinikum Heidelberg, Heidelberg, Germany
Erlotinib in Post Radical Operation NSCLC Patients With EGFR Mutation
- Conditions
- Interventions
- First Posted Date
- 2012-09-11
- Last Posted Date
- 2016-10-20
- Target Recruit Count
- 94
- Registration Number
- NCT01683175
- Locations
- 🇨🇳
The affiliated hospital of medical college Qingdao University, Qingdao, China
🇨🇳Zhejiang Cancer Hospital, Hangzhou, China
🇨🇳The third affiliated hospital of Harbin Medical Univer, Harbin, China
A Study to Assess Efficacy and Safety of Pertuzumab Given in Combination With Trastuzumab and Vinorelbine in Participants With Metastatic or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2-Positive Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2012-03-28
- Last Posted Date
- 2016-11-22
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 213
- Registration Number
- NCT01565083
Study to Compare Vinorelbine In Combination With the mTOR Inhibitor Everolimus vs. Vinorelbin Monotherapy for Second-line Treatment in Advanced Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2012-01-27
- Last Posted Date
- 2017-08-09
- Lead Sponsor
- AIO-Studien-gGmbH
- Target Recruit Count
- 139
- Registration Number
- NCT01520103
- Locations
- 🇩🇪
Hämatologisch-onkologische Gemeinschaftspraxis, Münster, Münster, Germany
Vinorelbine for Children With Progressive or Recurrent Low-grade Gliomas
- First Posted Date
- 2011-12-23
- Last Posted Date
- 2019-05-20
- Lead Sponsor
- Eugene Hwang
- Target Recruit Count
- 13
- Registration Number
- NCT01497860
- Locations
- 🇺🇸
Children's National Medical Center, Washington, District of Columbia, United States
🇺🇸Mayo Clinic, Rochester, Minnesota, United States
Lux-Breast 3; Afatinib Alone or in Combination With Vinorelbine in Patients With Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer Suffering From Brain Metastases
- Conditions
- Interventions
- First Posted Date
- 2011-09-27
- Last Posted Date
- 2015-09-07
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 121
- Registration Number
- NCT01441596
- Locations
- 🇰🇷
1200.67.82002 Boehringer Ingelheim Investigational Site, Seoul, Korea, Republic of
🇺🇸1200.67.10105 Boehringer Ingelheim Investigational Site, Fullerton, California, United States
🇺🇸1200.67.10108 Boehringer Ingelheim Investigational Site, Santa Barbara, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.